Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report
The most valuable drug in the pharma industry’s pipeline isn’t a new medicine for diabetes or cancer, but Vertex’s triple therapy for rare hereditary disease cystic fibrosis, according to EvaluatePharma.
That assertion ties in with its new report on worldwide prescription drug sales, which says that drugs for orphan diseases will outperform the overall pharma market, almost doubling to reach a whopping $262bn in 2024 when they will account for a fifth of all drug sales.
“This highlights the industry’s continued move to address small groups of neglected patients with high unmet need and to benefit from traditionally reduced payer scrutiny on orphan drugs, as well as regulatory and financial incentives,” says EP.
Read more: http://www.pmlive.com/pharma_news/drugs_for_rare_diseases_will_help_propel_pharma_sales_to_$1.2trn_by_2024_report_1238997
That assertion ties in with its new report on worldwide prescription drug sales, which says that drugs for orphan diseases will outperform the overall pharma market, almost doubling to reach a whopping $262bn in 2024 when they will account for a fifth of all drug sales.
“This highlights the industry’s continued move to address small groups of neglected patients with high unmet need and to benefit from traditionally reduced payer scrutiny on orphan drugs, as well as regulatory and financial incentives,” says EP.
Read more: http://www.pmlive.com/pharma_news/drugs_for_rare_diseases_will_help_propel_pharma_sales_to_$1.2trn_by_2024_report_1238997